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Breath tests are simple, noninvasive alternatives, which are
considered harmless for the diagnosis of Helicobacter pylori
(H. pylori) infection, small intestinal bacterial overgrowth
(SIBO), lactose intolerance (1), and inflammatory bowel
disease (2). In Brazil, the acquisition of 13C-urea from abroad
is challenging; however, with the support of the Division of
Pharmacy, 13C-urea breath tests were routinely performed in
clinical practice (3). Patients using anticoagulant drugs, with
low platelets count, cardiac impairment that contraindicates
endoscopy, or those who did not want to undergo upper
gastrointestinal endoscopy had the benefit of undergoing
13C-urea breath tests for H. pylori infection diagnosis, instead.
These scenarios changed abruptly by the middle of
March this year, when the cases of coronavirus disease 2019
(COVID-19), caused by the severe acute respiratory syn-
drome coronavirus-2 (SARS-CoV-2) (4) started to rise in
Brazil. According to WHO (https://covid19.who.int/), at
the beginning of June, there were 514,849 confirmed cases
and 29,314 deaths in Brazil. The performance of breath tests
usually considered risk-free, are currently threatened by
SARS-CoV-2 (5).
The symptoms of COVID-19 most commonly were fever,
cough and expectoration, sore throat, headache, fatigue, and
shortness of breath (6); conversely, some patients with mild
disease presented digestive symptoms (diarrhea, nausea,
and vomiting) with or without respiratory symptoms (7).
Diarrhea was the first symptom with or without fever, that
lasted from 1-14 days. These patients with digestive symp-
toms had longer a duration between disease onset and viral
clearance, with positive RNA virus in the feces, than those
with respiratory symptoms (7).
Patients with lactose intolerance, irritable bowel syn-
drome, and SIBO usually have diarrhea (1); thus, caution
must be taken, as patients with only diarrhea may be
harboring SARS-CoV-2, and may unknowingly spread the
virus (7) in clinical investigations using H2 breath tests to
detect lactose intolerance or SIBO (1). To exclude lactose
intolerance, a genetic test is a safer choice than the lactose
breath test (8).
The instruments to measure H2, generated by bacterial
fermentation of carbohydrates, in end-alveolar breath sam-
ples, may be stationary (CM2 microlyzer, Breath tracker
analyzer) or portable (Gastrolyzer, Easy H2). When using
stationary equipment, the patient blows into a plastic device,
consisting of a mouthpiece and T valve attached to a plastic
bag. The breath is aspirated into a 30 mL syringe attached to
the T valve (8). When using portable equipment, the patient
inspires the air deeply, holds the air inside the lung for
15 seconds, and then blows all the air into a mouthpiece
attached to the equipment. The patient forces expiration that
generates respiratory droplets and aerosols. Viral RNA was
detected in respiratory droplets and aerosols from corona-
virus-, influenza virus-, and rhinovirus-infected patients (9).
The patient blows the H2 baseline collection and several
times after swallowing a carbohydrate substrate. The exam
lasts 1 hour and 20 minutes for SIBO and three hours for
lactose intolerance. The test carries risks of contamination to
the healthcare worker collecting the breath samples and to
the patients, as the ultrafine aerosol droplets may also carry
SARS-CoV-2 and remain airborne for long periods, and
could be inhaled (5).
For the 13C-urea breath test for H. pylori infection diag-
nosis, the patient blows into a plastic mouthpiece attached to
an aluminized bag. Patients inspire the air and blow with
strain until the bag is completely full of air. Sometimes it
stimulates cough. Breath samples are collected before and
after ingesting a 13C-urea capsule (3). Although the test lasts
20 minutes, it carries the risk of contamination by SARS-
CoV-2 in the aerosol droplets generated by the exhaled
air (5).
One possibility to overcome the risks of contamination is a
pre-procedural mouth rinse, including chlorhexidine, cetyl-
pyridinium chloride, and essential oils that decreases the
proportion of microorganisms in oral aerosols, and leads to
a mean reduction of 68.4% colony-forming units in dental
aerosols. The impact on coronavirus is uncertain; however, it
is efficient against human immunodeficiency, herpes sim-
plex, and hepatitis B viruses (10). Wearing protective glasses,
face shields, surgical masks, or particulate respirator Health-
certified N95, or equivalent (10), may protect the healthcare
worker, but not the patient that has to blow inside a room
with oral aerosols, generated by previous exams. Patient
selection should be done based on a negative swab forDOI: 10.6061/clinics/2020/e2092
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SARS-CoV-2 by real-time reverse transcription-PCR; how-
ever, the nasopharyngeal swab specimen has to be properly
collected by inserting deeply into the nasal cavity, or it can
produce a false negative (11). Other analytical assays for
SARS-CoV-2 diagnosis include antigen detection by lateral
flow assays that are fast and low cost; nonetheless, these tests
lack good sensitivity early in the infection stage (11).
Serology detection, an indirect method, is reliable to indicate
past infection than active ones (11). It would be better to wait
for a vaccine before resuming breath tests again, but it is
unknown how long that will take.
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